Cardiff has enjoyed a long relationship with China spanning decades. However, the past decade has witnessed a greater effort in the development of collaboration in the fight against cancer, in research, in education, in healthcare and indeed in other health and social related sections in cancer care. Cardiff has particularly enjoyed strong partnerships with Peking University, Capital Medical University and Yiling Group, which covers broad areas of research, R&D to medicines and healthcare. These links have resulted in some fruitful outcomes, from student/scientist exchanges, joint research publications, new diagnosis, and new medicines and together we host our annual CUKC Conference. Our success is now recognised by several awards including the China-UK Cancer Research International Base (Beijing), the Key Laboratories of Cancer Metastasis by the Beijing Government and of course by the TIMES Higher Education International Collaboration of the Year award.
Founded in 1883, Cardiff University is established as one of the Britain’s leading research universities. We excel in producing high quality, innovative research which directly translates to deliver benefits locally and worldwide.
We have a diverse student population with students coming from more than 100 countries and with a range of backgrounds. Our academic staff are driven by creativity and curiosity and many are leaders in their fields, creating a stimulating environment for learning.
Our research earns grants and investments totalling tens of millions of pounds and attracts top researchers from around the world. We’re part of the Russell Group of 24 leading research intensive UK universities. Our research staff are world-class and include Nobel Laureates, Fellows of the Royal Society and members of other prestigious institutions. Our research expertise and facilities are used by industry and commercial partners, government bodies and other organisations internationally. We help to generate business ideas and spin-out companies and contribute to economic growth and job creation in Wales and beyond. Our research contracts have a total value of £500M.
Since its foundation in 1893, Cardiff’s School of Medicine has been committed to the pursuit of improved human health, through education, research and engagement with the wider world. We are a major centre for teaching and research and make a positive difference to the way medicine is practised in Wales, the UK and internationally.
Founded in 1898, Peking University is the top ranked university in China and one of the premier universities in the world. It is one of the top 5 Higher Education Institutions in Asia and its research, teaching and international activities are recognised worldwide for their excellence. It is also a leading cancer research and cancer service in China. Some of China’s leading cancer experts work at Peking University Cancer Hospital. Peking University Cancer Hospital physicians provide patient-oriented medical services in a wide variety of cancer specialties treating gastric cancer, breast cancer, lung cancer, colorectal cancer, liver cancer, esophageal carcinoma, lymphoma, melanoma, and much more.
The Cardiff University – Peking University Cancer Institute (CUPUCI) was established in 2013. Cardiff University has been collaborating with Peking University in Beijing for over a decade and has hosted a large number of their cancer scientists and specialists over the years. CUPUCI consists of two designated research centres, one located at each university. These centres provide a true home and state-of-the-art facilities for our Fellows and PhD students to collaborate more effectively. At Peking, the Institute is located in its nation’s renowned Peking University Cancer Hospital and Beijing Cancer Institute. Currently, the Cardiff – Peking Cancer Institute research focus is on some of the most aggressive forms of cancer, including gastrointestinal cancers, pancreatic cancer lung cancer and esophageal carcinoma, which are amongst the priority areas in healthcare and cancer research in both the UK and China. Research work also concentrates on cancer metastasis, angiogenesis, biomarkers and new methods of cancer treatment, including alternative medicine such as traditional Chinese medicine.
Capital Medical University (CMU) was founded in 1960. It ranks amongst the top academic medical institutions in China and is considered to be one of the key municipal Universities in Beijing. CMU consists of ten schools, twenty affiliated hospitals and one teaching institution. The University has 10,132 enrolled students and offers a diverse spectrum of undergraduate, graduate, doctoral and specialized degree programs to meet the varied needs of its students. It is purported to be the world’s largest medical university, with 20 affiliated hospitals and more than 16,500 hospital beds. It delivers a full range of health, medicine and life science related subjects at all levels.
The Cancer Institute of Capital Medical University was formed in 2011, when Professor HongtiJia became the first Director. Since 2013, Professor Wenguo Jiang has been the Director. Cardiff University and Capital Medical University (CMU) have enjoyed a long and fruitful relationship in research and education since 2003 and in 2012, the Cardiff University – Capital Medical University Joint Centre for Biomedical Research was established.
This Centre has created opportunities for research in a number of medical fields. In particular, research has been advancing on the metastasis of breast cancer examining how the disease spreads around the body. To date, our collaborative research has discovered new biomarkers for not only breast cancer but also for prostate and kidney cancer. Other research projects have focused on brain metastasis and gastrointestinal cancers. In future, the scope could expand to include areas such as neurology, dentistry, nursing and tissue repair.
Cardiff’s relationship with CMU has led to the introduction of a Cardiff University China Medical Scholarship. The Scholarship has already supported more than 50 Chinese medics in the last 5 years to spend time in Cardiff for research training, clinical experience and education.
Yiling Group Medical Research Institute was formed in 1992 by Professor Yiling Wu, a highly accomplished scientist, medic, academician, entrepreneur and politician in China. Yiling Pharmaceuticals is one of China’s high-tech pharmaceutical companies, devoted to R&D, manufacture and marketing of new medicines. It has some unique approaches in therapeutic development for diseases such as arrhythmia, heart failure, bird flu and cancer.
Cardiff University has been collaborating with Yiling Group since 2011, initially investigating the potential mechanism(s) of some anti-cancer medicines. In 2013, the Cardiff University – Yiling Group Joint Medical Research Centre was established to focus on developing and advancing new treatments for cancer and infectious diseases, with a particular focus on Chinese medicine.
The team at Cardiff, along with colleagues at Peking University and the team at Yiling, have together been testing the health benefits of the Chinese herbal medicine in cancer treatment. Some of the herbal medicines had previously been shown to be beneficial to cancer patients but until this latest research the way in which it works had remained unknown. The joint research investigated how the formula works and discovered that it blocks a pathway, reducing the spread of cancer cells in the body. The Chinese formula has been shown to be beneficial to patients with certain solid tumours, when used alone and in conventional therapies such as chemotherapy.
Cardiff’s collaboration with Yiling has also allowed the creation of new scholarship opportunities for Chinese medical scholars enabling them to undertake study and training in the UK. Likewise, UK students will be able to gain overseas experience by spending time with Cardiff’s partners in China. The Joint Centre, which focuses on translational and clinical research, will in future, look to extend the research collaboration to other areas of medicine in addition to cancer.